Pilot trial of infusional 5-fluorouracil, interleukin-2, and subcutaneous interferon-α for advanced renal cell carcinoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 22, Issue 2, 1999, Pages 156-161

  Elias, Laurence ^a,d   Binder, Mitchell ^a   Mangalik, Aroop ^a   Clark, Douglas ^a,c   Morrison, Betsy ^b   Altobelli, Kathleen K ^a   Smith, Anthony ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b Lovelace Bataan Medical Center   (United States)

^c Albuquerque MA Medical Center   (United States)

^d UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

5 Fluorouracil; Interferon ; Interleukin 2; Renal cell carcinoma

Indexed keywords

ALPHA2B INTERFERON; FLUOROURACIL; INTERLEUKIN 2;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; KIDNEY CARCINOMA; MALE; OUTPATIENT CARE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PILOT STUDY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; INTERFERON-ALPHA; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PILOT PROJECTS; SURVIVAL ANALYSIS;

EID: 0033512367     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199904000-00010     Document Type: Article

References (40)

1. Bukowski RM. Natural history and therapy of metastatic renal cell carcinoma. The role of interleukin-2. Cancer 1997;80:1198-220.
2. Yang JC, Rosenberg SA. An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer. Sci Amer Cancer J 1997;3:S79-S84.
3. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 1998;338:1272-8.
4. Wadler S, Schwartz EL. Biologic agents as biochemical modulators: pharmacologic basis for the interaction of cytotoxic chemotherapeutic drugs and interferon. Cancer Chemother Pharmacol 1994;35:21-30.
5. Elias L, Crissman HA. Interferon effects upon adenocarcinoma 38 and HL-60 cell lines: antiproliferative responses and synergistic interactions with halogenated pyrimidine antimetabolites. Cancer Res 1988;48:4868-73.
6. Elias L, Sandoval JM. Interferon effects upon fluorouracil metabolism by HL-60 cells. Biochem Biophys Res Commun 1989;163: 867-74.
7. Schwartz EL, Hoffman M, O'Connor CJ, Wadler S. Stimulation of 5-fluorouracil metabolic activation by interferon-α in human colon carcinoma cells. Biochem Biophys Res Commun 1992;182:1232-9.
8. Chu E, Koeller DM, Johnston PG, Zinn S, Allegra CJ. Regulation of thymidylate synthase in human colon cancer cells treated with 5-fluorouracil and interferon-τ. Mol Pharmacol 1993;43:527-33.
9. Haarstad H, Jacobsen AB, Schjlseth SA, Risberg T, Fossa SD. Interferon-alpha, 5-FU and prednisone in metastatic renal cell carcinoma: a phase II study. Ann Oncol 1994;5:245-8.
10. Schuth J, Goldschmidt AJ, Tunn UW. Response in patients with metastatic renal cell carcinoma (RCC) during the treatment with alpha interferon in combination with 5-fluorouracil [Abstract 1311]. Eur J Cancer 1993;29(suppl 6):234.
11. Murphy BR, Rynard SM, Einhorn LH, Loehrer PJ. A phase II trial of interferon alpha-2A plus fluorouracil in advanced renal cell carcinoma. A Hoosier Oncology Group Study. Invest New Drugs 1992;10:225-30.
12. Elias L, Blumenstein BA, Kish J, et al. A phase II trial of interferon-α and 5-fluorouracil in patients with advanced renal cell carcinoma. A Southwest Oncology Group Study. Cancer 1996;78: 1085-8.
13. Greenblatt MS, Mangalik A, Ferguson J, Elias L. Phase I evaluation of therapy with four schedules of 5-fluorouracil by continuous infusion combined with recombinant interferon-α. Clinical Cancer Research 1995;1:615-20.
14. Leichman CG. Prolonged infusion of fluorinated pyrimidines in gastrointestinal malignancies: a review of recent clinical trials. Cancer Invest 1994;12:166-75.
15. Hirsh M, Lipton AI, Harvey H, et al. Phase I study of interleukin-2 and interferon alfa-2a as outpatient therapy for patients with advanced malignancy. J Clin Oncol 1990;8:1657-63.
16. Figlin RA, Belldegrun A, Moldawer N, Zeffren J, de Kernion J. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma. J Clin Oncol 1992;10:414-21.
17. Kish JA, Wolf M, Crawford ED, Leimert JT, Bueschen A, Neefe JR, Flanigan RC. Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group study. Cancer 1994;74: 916-9.
18. Neefe JR, John W. Mechanisms of interaction of interferon and 5-fluorouracil in solid tumors. Semin Oncol 1991;18(suppl 7):77-82.
19. Reiter Z, Ozes ON, Blatt LM, Taylor MW. A dual anti-tumor effect of combination of interferon-alpha or interleukin-2 and 5-fluorouracil on natural killer (NK) cell-mediated cytotoxicity. Clin Immunol Immunopathol 1992;62:103-11.
20. Onodera H, Somers SS, Guillou PJ. Paradoxical effects of 5-fluorouracil/folinic acid on lymphokine-activated killer (LAK) cell induction in patients with colorectal cancer. Br J Cancer 1990;62: 1042-6.
21. Atzpodien J, Kirchner H, Hanninen EL, Decken M, Fenner M, Poliwoda H. Interleukin-2 in combination with interferon-α and 5-fluorouracil for metastatic renal cell cancer. Eur J Cancer 1993;29A(suppl 5):S6-S8.
22. Ellerhorst JA, Sella A, Amato RJ, et al. Phase II trial of 5-fluorouracil, interferon-α and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma. Cancer 1997;80:2128-32.
23. Palmer PA, Vinke J, Philip T, et at. Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol 1992;3:475-80.
24. Jones M, Philip T, Palmer P, et al. The impact of interleukin-2 on survival in renal cancer: A multivariate analysis. Cancer Biother 1993;8:275-88.
25. Lissoni P, Barni S, Ardizzoia A, et al. Prognostic factors of the clinical response to subcutaneous immunotherapy with interleukin-2 alone inpatients with metastatic renal cell carcinoma. Oncology 1994;51:59-62.
26. Canobbio L, Rubagotti A, Miglietta L, Cannata D, Curotto A, Amoroso D, Boccardo F. Prognostic factors for survival in patients with advanced renal cell carcinoma treated with interleukin-2 and interferon-α. J Cancer Res Clin Oncol 1995;121:753-6.
27. Srigley JR, Hutter RVP, Gelb AB, et al. Current prognostic factors - renal cell carcinoma. Cancer 1997;80:994-6.
28. Atzpodien J, Kirchner H, Franzke A, et al. Results of a randomized clinical trial comparing SC interleukin-2, SC alpha-2a-interferon, and IV bolus 5-fluorouracil against oral tamoxifen in progressive metastatic renal cell carcinoma patients [abstract 1164]. Proceedings of the American Society of Clinical Oncology 1997;16:326a.
29. Joffe JK, Banks RE, Forbes MA, et al. A phase II study of interferon-α, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: clinical data and laboratory evidence of protease activation. Br J Urol 1996;77:638-49.
30. Hanninen EL, Kirchner H, Atzpodien J. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol 1996;155:19-25.
31. Hofmockel G, Langer W, Theiss M, Gruss A, Frohmuller HGW. Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-α and 5-fluorouracil. J Urol 1996;156:18-21.
32. Dutcher JP, Atkins M, Fisher R, et al. Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997. Sci Amer Cancer J 1997;3:S73-8.
33. Holroyde CP, Luginbuhl WE, Pascale RL, Armstead B, Malkowicz SB, Vaughn DJ. Phase II trial of low dose interleukin-2 with 5-fluorouracil, leucovorin, and interferon alfa-2b in patients with metastatic renal cell carcinoma: a Penn Cancer Clinical Trials Group study [abstract 1288]. Proceedings of the American Society of Clinical Oncology 1998;17:334a.
34. Gitlitz BJ, Dolan N, Pierce W, deKernion J, Belldegrun A, Figlin RA. Fluoropyrimidines plus interleukin-2 and interferon-α in the treatment of metastatic renal cell carcinoma: the UCLA Kidney Cancer Program [abstract 630]. Proceedings of the American Society of Clinical Oncology 1996;15:248.
35. Ventriglia M, Estevez R, Tiscomia A. Chemoimmunotherapy with interleukin-2 (IL2) proleukin®, interferon alfa 2b (IFN): and 5 fluorouracil (5FU) in outpatients with advanced renal cell carcinoma (ARCC) [abstract 1339]. Proceedings of the American Society of Clinical Oncology 1998;17:347a.
36. Negrier S, Escudier B, Douillard JY, et al. Randomized study of interleukin-2 and interferon with or without 5-FU (FUCY study) in metastatic renal cell carcinoma [abstract 1161]. Proceedings of the American Society of Clinical Oncology 1997;16:326a.
37. Miller BA, Kolonel LN, Bernstein L, et al. Racial/Ethnic Patterns of Cancer in the United States 1988-1992. Bethesda, Md: National Cancer Institute; 1996. Publication 96-4104.
38. Schendel DJ, Gansbacher B, Oberneder R, Kriegmair M, Hofstetter A, Riethmuller G, Segurado OG. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines. J Immunol 1993;151:4209-20.
39. Bain C, Merrouche Y, Puisieux I, et al. Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma. Br J Cancer 1997;75:283-6.
40. Fleming S. Genetics of renal tumors. Cancer Metastasis Rev 1997;16:127-40.